Circovirus sequences associated with piglet weight loss disease (PWD)
View Patent ↗The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1. A method for detecting porcine circovirus (PCV), comprising:
(a) contacting a sample with a peptide selected from the group consisting of SEQ ID NOS: 29-32 and 55-60;
(b) detecting binding between the serum and the peptide; and
(c) correlating binding with the presence of PCV in said sample.
2. The method of claim 1 , wherein the sample is obtained from a pig.
3. The method of claim 2 , wherein the sample is serum.
4. The method of claim 3 , wherein detecting the presence of PCV is correlated with infection by said PCV.
5. The method of claim 1 , wherein the detecting step is performed by enzyme-linked immunosorbent assay (ELISA).
6. The method of claim 1 , wherein the peptide is labeled with a detectable marker.
7. The method of claim 1 , wherein the peptide is selected from the group consisting of SEQ ID NOS: 29-32 and 58.
8. The method of claim 7 , wherein the peptide binds to serum from a pig infected with PCVB, but not with serum from a pig infected with porcine circovirus type A (PCVA).
9. A peptide selected from the group consisting of SEQ ID NOS: 29-32 and 55-60.
10. The peptide of claim 9 , wherein said peptide is selected from the group consisting of SEQ ID NOS: 29-32 and 58.
11. The peptide of claim 10 , wherein the peptide binds to serum from a pig infected with PCVB, but not with serum from a pig infected with porcine circovirus type A (PCVA).
12. The peptide of claim 9 , which is detectably labeled.
13. The peptide of claim 9 , wherein said peptide elicits an immune response to PCVB when injected into a pig.
14. The peptide of claim 10 , wherein said peptide elicits an immune response to PCVB when injected into a pig.
15. An immunogenic composition comprising the peptide of claim 13 , and a pharmaceutically acceptable carrier.
16. An immunogenic composition comprising the peptide of claim 14 , and a pharmaceutically acceptable carrier.
17. A vaccine comprising the peptide of claim 13 , and a pharmaceutically acceptable carrier.
18. A vaccine comprising the peptide of claim 14 , and a pharmaceutically acceptable carrier.
19. A method of inducing antibodies against PCVB, comprising administering the peptide of claim 13 , to a mammal.
20. A method of inducing antibodies against PCVB, comprising administering the peptide of claim 14 , to a mammal.
21. A method of treating or preventing infection by PCV, comprising administering the vaccine of claim 17 , to a pig.
22. A method of treating or preventing infection by PCV, comprising administering the vaccine of claim 18 , to a pig.